Open Access

Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line Chemotherapy

SEI MORINAGA 1 2 3
QINGHONG HAN 1
KOHEI MIZUTA 1 2
BYUNG MO KANG 1 2
NORIO YAMAMOTO 3
KATSUHIRO HAYASHI 3
HIROAKI KIMURA 3
SHINJI MIWA 3
KENTARO IGARASHI 3
TAKASHI HIGUCHI 3
HIROYUKI TSUCHIYA 3
SATORU DEMURA 3
  &  
ROBERT M. HOFFMAN 1 2

1AntiCancer Inc., San Diego, CA, U.S.A.

2Department of Surgery, University of California, San Diego, CA, U.S.A.

3Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

Cancer Diagnosis & Prognosis Jan-Feb; 5(1): 21-26 DOI: 10.21873/cdp.10407
Received 05 August 2024 | Revised 19 February 2025 | Accepted 30 August 2024
Corresponding author
Robert M. Hoffman, Ph.D., AntiCancer Inc, 7917 Ostrow St, Suite B, San Diego, CA, 92111, U.S.A. Tel: +1 6198852284 all@anticancer.com
pdf image icon

Abstract

Background/Aim: Chronic lymphocytic leukemia (CLL) is currently incurable. CLL is characterized by disordered DNA methylation. The aim of the present study was to target methylation with methionine restriction in a patient with progressive CLL. Case Report: Methionine restriction for the patient was achieved with a low-methionine vegan diet and oral recombinant methioninase (o-rMETase). The patient also received rituximab, once per week for four weeks, and acalabrutinib 100 mg, twice daily (bid) continuously. The patient’s white blood cell count decreased by 95% from peak levels and extensive lymphadenopathy disappeared during combination treatment with o-rMETase, rituximab, and acalabrutinib. Conclusion: The combination of methionine restriction and first-line chemotherapy resulted in an apparent complete response (CR) in a CLL patient, a rare event. The duration of the CR will be monitored, and additional CLL patients will be treated similarly in the future.
Keywords: Chronic lymphocytic leukemia, CLL, Methionine restriction, methioninase, rituximab, acalabrutinib, first-line chemotherapy, combination therapy, complete response

Chronic lymphocytic leukemia (CLL) is the result of overproduction of B lymphocytes which accumulate both in the blood circulation and in lymph nodes (1). CLL is characterized by a decrease in global DNA methylation compared with normal B-lymphocytes, along with increased DNA methylation of CpG islands (2) that may decrease the expression of genes that are necessary for drug sensitivity (3). Global DNA hypomethylation in cancer was discovered by one of us (RMH) in 1982 (4).

First-line therapy for CLL includes inhibitors of Bruton’s tyrosine kinase (BTK), such as ibrutinib and acalabrutinib, as well as rituximab, fludarabine and cyclophosphamide (5-8). However, CLL remains incurable, despite patient responses, which generally are not durable (9).

Given that methylation is aberrant in CLL, we treated a CLL patient who was rapidly progressing with methionine restriction (MR) effected by oral recombinant methioninase (o-rMETase) and a low-methionine diet combined with first-line chemotherapy, resulting in an apparent complete response.

Case Report

The patient is an 85-year-old female that was diagnosed with CLL in 2019 while being treated for an abdominal sarcoma. The patient began MR, including an MR diet and was also treated with o-rMETase (10-16), which was purified from recombinant E. coli containing the Pseudomonas putida methioninase gene, as previously described (17). The patient received o-rMETase after each meal (250 units/1 ml). The patient was also treated with rituximab q week ×4 and acalabrutinib 100 mg twice daily (bid) continuously.

The patient started o-rMETase and the MR diet in September 2022. At this time, her white blood cell (WBC) count was 108×103/μl. The WBC continued to rise, reaching 195×103/μl by February 2023, at which point rituximab was initiated for one month. In March 2023, acalabrutinib was initiated, leading to a steep decline in the WBC count, which reached 8.1×103/μl in December 2023, which is within the normal range. WBC counts were 8.6×103/μl in January 2024 and 9.1×103/μl in June 2024 (Figure 1).

In January 2023, the patient had enlarged mediastinal and right-axillary-lymph-node adenopathy. For example, a right axillary lymph node was 18 mm in the short axis and a paratracheal lymph node was 9 mm in the short axis, observed using chest/abdominal/pelvis computed tomography (CT) with intravenous injection of a contrast agent.

By November 2023, no evidence of lymphadenopathy or disease progression was observed in the chest, abdominal or pelvis on CT scans. An apparent complete response (CR) was assumed based on the WBC count and CT of the lymph nodes. The CR appears durable as the patient continues to have a low WBC count as of September 2024.

Discussion

CLL is indolent in some patients and aggressive in others. It is considered incurable (21). CLL is characterized by disordered DNA methylation, which can cause clonal heterogeneity, including drug resistance and more aggressive progression (2).

In the present study, at the start of MR, with o-rMETase and the MR diet, the patient continued to progress. However, when acalabrutinib was added to MR, the patient’s WBC count rapidly declined to normal, and lymphadenopathy disappeared in an apparent CR. The present study suggests that MR in combination with first-line chemotherapy was effective.

Very recent studies suggested that inhibiting the anti-apoptotic protein BCL-2 in CLL via venetclax in combination with the BTK inhibitor ibrutinib increases survival in CLL compared to the combination of fludarabine, cyclophosphamide and rituximab (FCR) (19). MR could be added to this regimen as well. A new BTX inhibitor for CLL, pirobrutinib, has also shown promising results (20).

MR is synergistic with all types of chemotherapy in preclinical mouse models of cancer including patient-derived orthotopic xenograft (PDOX) models (12-46). MR combined with chemotherapy may be synergistic in the clinic as suggested by the present and previous reports (12-16,22,46).

MR is effective as it targets the fundamental and universal hallmark of cancer, methionine addiction, termed the Hoffman effect (21,47-68).

Conflicts of Interest

The Authors declare no competing interests in relation to this study.

Authors’ Contributions

SM was a major contributor to writing the manuscript and RMH revised the paper. QH produced o-rMETase, KM, BMK, MS, MB, NY, KH, HK, SM, KI, TH, HT and SD critically read and approved the final manuscript.

Acknowledgements

This paper is dedicated to the memory of A.R. Moosa, MD, Sun Lee, MD, Professor Gordon H. Sato, Professor Li Jiaxi, Masaki Kitajima, MD, Shigeo Yagi, PhD, Jack Geller, MD, Joseph R Bertino, MD, J.A.R. Mead, PhD, Eugene P. Frenkel, MD, Professor Lev Bergelson, Professor Sheldon Penman, Professor John R. Raper and Joseph Leighton, MD.

References

1 Mukkamalla SKR Taneja A Malipeddi D & Master SR Chronic Lymphocytic Leukemia. StatPearls Publishing.
2 Landau DA Clement K Ziller MJ Boyle P Fan J Gu H Stevenson K Sougnez C Wang L Li S Kotliar D Zhang W Ghandi M Garraway L Fernandes SM Livak KJ Gabriel S Gnirke A Lander ES Brown JR Neuberg D Kharchenko PV Hacohen N Getz G Meissner A & Wu CJ Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 26(6) 813 - 825 2014. DOI: 10.1016/j.ccell.2014.10.012
3 Barrow TM Nakjang S Lafta F Bilotkach K Woodhouse L Junge G Tudhope SJ Wallis JP Marr H Marshall S Bown N Willmore E & Strathdee G Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia. Br J Cancer. 124(2) 474 - 483 2021. DOI: 10.1038/s41416-020-01117-8
4 Diala ES & Hoffman RM Hypomethylation of HeLa cell DNA and the absence of 5-methylcytosine in SV40 and adenovirus (type 2) DNA: Analysis by HPLC. Biochem Biophys Res Commun. 107(1) 19 - 26 1982. DOI: 10.1016/0006-291x(82)91663-1
5 Eichhorst BF Busch R Hopfinger G Pasold R Hensel M Steinbrecher C Siehl S Jäger U Bergmann M Stilgenbauer S Schweighofer C Wendtner CM Döhner H Brittinger G Emmerich B Hallek M & German CLL Study Group Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 107(3) 885 - 891 2005. DOI: 10.1182/blood-2005-06-2395
6 Byrd JC Peterson BL Morrison VA Park K Jacobson R Hoke E Vardiman JW Rai K Schiffer CA & Larson RA Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101(1) 6 - 14 2003. DOI: 10.1182/blood-2002-04-1258
7 Keating MJ O’Brien S Albitar M Lerner S Plunkett W Giles F Andreeff M Cortes J Faderl S Thomas D Koller C Wierda W Detry MA Lynn A & Kantarjian H Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 23(18) 4079 - 4088 2005. DOI: 10.1200/JCO.2005.12.051
8 St-Pierre F & Ma S Use of BTK inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a practical guidance. Blood Lymphat Cancer. 12 81 - 98 2022. DOI: 10.2147/BLCTT.S326627
9 O’Donnell A Pepper C Mitchell S & Pepper A NF-kB and the CLL microenvironment. Front Oncol. 13 1169397 2023. DOI: 10.3389/fonc.2023.1169397
10 Tan Y Zavala J Han Q Xu M Sun X Tan X Tan X Magana R Geller J & Hoffman RM Recombinant methioninase infusion reduces the biochemical endpoint of serum methionine with minimal toxicity in high-stage cancer patients. Anticancer Res. 17 3857 - 3860 1997.
11 Han Q Tan Y & Hoffman RM Oral dosing of recombinant methioninase is associated with a 70% drop in PSA in a patient with bone-metastatic prostate cancer and 50% reduction in circulating methionine in a high-stage ovarian cancer patient. Anticancer Res. 40(5) 2813 - 2819 2020. DOI: 10.21873/anticanres.14254
12 Kubota Y Han Q Hozumi C Masaki N Yamamoto J Aoki Y Tsunoda T & Hoffman RM Stage IV pancreatic cancer patient treated with FOLFIRINOX combined with oral methioninase: a highly-rare case with long-term stable disease. Anticancer Res. 42(5) 2567 - 2572 2022. DOI: 10.21873/anticanres.15734
13 Kubota Y Han Q Hamada K Aoki Y Masaki N Obara K Tsunoda T & Hoffman RM Long-term stable disease in a rectal-cancer patient treated by methionine restriction with oral recombinant methioninase and a low-methionine diet. Anticancer Res. 42(8) 3857 - 3861 2022. DOI: 10.21873/anticanres.15877
14 Kubota Y Han Q Masaki N Hozumi C Hamada K Aoki Y Obara K Tsunoda T & Hoffman RM Elimination of axillary-lymph-node metastases in a patient with invasive lobular breast cancer treated by first-line neo-adjuvant chemotherapy combined with methionine restriction. Anticancer Res. 42(12) 5819 - 5823 2022. DOI: 10.21873/anticanres.16089
15 Kubota Y Han Q Morinaga S Tsunoda T & Hoffman RM Rapid reduction of CEA and stable metastasis in an NRAS-mutant rectal-cancer patient treated with FOLFIRI and bevacizumab combined with oral recombinant methioninase and a low-methionine diet upon metastatic recurrence after FOLFIRI and bevacizumab treatment alone. In Vivo. 37(5) 2134 - 2138 2023. DOI: 10.21873/invivo.13310
16 Sato M Han Q Mori R Mizuta K Kang BM Morinaga S Kobayashi N Ichikawa Y Nakajima A & Hoffman RM Reduction of tumor biomarkers from very high to normal and extensive metastatic lesions to undetectability in a patient with stage IV HER2-positive breast cancer treated with low-dose trastuzumab deruxtecan in combination with oral recombinant methioninase and a low-methionine diet. Anticancer Res. 44(4) 1499 - 1504 2024. DOI: 10.21873/anticanres.16946
17 Tan Y Xu M Tan X Tan X Wang X Saikawa Y Nagahama T Sun X Lenz M & Hoffman RM Overexpression and large-scale production of recombinantl-methionine-α-deamino-γ-mercaptomethane-lyase for novel anticancer therapy. Protein Expr Purif. 9(2) 233 - 245 1997. DOI: 10.1006/prep.1996.0700
18 Ferrer G & Montserrat E Critical molecular pathways in CLL therapy. Mol Med. 24(1) 9 2018. DOI: 10.1186/s10020-018-0001-1
19 Munir T Cairns DA Bloor A Allsup D Cwynarski K Pettitt A Paneesha S Fox CP Eyre TA Forconi F Elmusharaf N Kennedy B Gribben J Pemberton N Sheehy O Preston G Schuh A Walewska R Duley L Howard D Hockaday A Jackson S Greatorex N Girvan S Bell S Brown JM Webster N Dalal S de Tute R Rawstron A Patten PEM Hillmen P & National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 390(4) 326 - 337 2024. DOI: 10.1056/NEJMoa2310063
20 Mato AR Woyach JA Brown JR Ghia P Patel K Eyre TA Munir T Lech-Maranda E Lamanna N Tam CS Shah NN Coombs CC Ujjani CS Fakhri B Cheah CY Patel MR Alencar AJ Cohen JB Gerson JN Flinn IW Ma S Jagadeesh D Rhodes JM Hernandez-Ilizaliturri F Zinzani PL Seymour JF Balbas M Nair B Abada P Wang C Ruppert AS Wang D Tsai DE Wierda WG & Jurczak W Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 389(1) 33 - 44 2023. DOI: 10.1056/NEJMoa2300696
21 Hoffman RM Development of recombinant methioninase to target the general cancer-specific metabolic defect of methionine dependence: a 40-year odyssey. Expert Opin Biol Ther. 15(1) 21 - 31 2015. DOI: 10.1517/14712598.2015.963050
22 Sato M Han Q Hozumi C Kujiraoka H Mizuta K Morinaga S Kang BM Kobayashi N Ichikawa Y Nakajima A & Hoffman RM First-line chemotherapy in combination with oral recombinant methioninase and a low-methionine diet for a stage IV inoperable pancreatic-cancer patient resulted in 40% tumor reduction and an 86% CA19-9 biomarker decrease. Anticancer Res. 44(9) 3885 - 3889 2024. DOI: 10.21873/anticanres.17215
23 Stern PH & Hoffman RM Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst. 76(4) 629 - 639 1986. DOI: 10.1093/jnci/76.4.629
24 Higuchi T Sugisawa N Yamamoto J Oshiro H Han Q Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Tan Y Kuchipudi S Bouvet M Singh SR Tsuchiya H & Hoffman RM The combination of oral-recombinant methioninase and azacitidine arrests achemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. Cancer Chemother Pharmacol. 85(2) 285 - 291 2020. DOI: 10.1007/s00280-019-03986-0
25 Masaki N Han Q Wu NF Samonte C Wu J Hozumi C Obara K Kubota Y Aoki Y Miyazaki J & Hoffman RM Oral-recombinant methioninase lowers the effective dose and eliminates toxicity of cisplatinum for primary osteosarcoma of the mammary gland in a patient-derived orthotopic xenograft mouse model. In Vivo. 36(6) 2598 - 2603 2022. DOI: 10.21873/invivo.12994
26 Masaki N Han Q Samonte C Wu NF Hozumi C Wu J Obara K Kubota Y Aoki Y Bouvet M & Hoffman RM Oral-recombinant methioninase in combination with rapamycin eradicates osteosarcoma of the breast in a patient-derived orthotopic xenograft mouse model. Anticancer Res. 42(11) 5217 - 5222 2022. DOI: 10.21873/anticanres.16028
27 Aoki Y Tome Y Han Q Yamamoto J Hamada K Masaki N Kubota Y Bouvet M Nishida K & Hoffman RM Oral-recombinant methioninase converts an osteosarcoma from methotrexate-resistant to -sensitive in a patient-derived orthotopic-xenograft (PDOX) mouse model. Anticancer Res. 42(2) 731 - 737 2022. DOI: 10.21873/anticanres.15531
28 Aoki Y Tome Y Wu NF Yamamoto J Hamada K Han Q Bouvet M Nishida K & Hoffman RM Oral-recombinant methioninase converts an osteosarcoma from docetaxel-resistant to -sensitive in a clinically-relevant patient-derived orthotopic-xenograft (PDOX) mouse model. Anticancer Res. 41(4) 1745 - 1751 2021. DOI: 10.21873/anticanres.14939
29 Yamamoto J Miyake K Han Q Tan Y Inubushi S Sugisawa N Higuchi T Tashiro Y Nishino H Homma Y Matsuyama R Chawla SP Bouvet M Singh SR Endo I & Hoffman RM Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 492 174 - 184 2020. DOI: 10.1016/j.canlet.2020.07.034
30 Higuchi T Han Q Miyake K Oshiro H Sugisawa N Tan Y Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Bouvet M Singh SR Tsuchiya H & Hoffman RM Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun. 523(1) 135 - 139 2020. DOI: 10.1016/j.bbrc.2019.12.024
31 Miyake M Miyake K Han Q Igarashi K Kawaguchi K Barangi M Kiyuna T Sugisawa N Higuchi T Oshiro H Zhang Z Razmjooei S Bouvet M Endo I & Hoffman RM Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer. Biochem Biophys Res Commun. 643 48 - 54 2023. DOI: 10.1016/j.bbrc.2022.12.062
32 Higuchi T Oshiro H Miyake K Sugisawa N Han Q Tan Y Park J Zhang Z Razmjooei S Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Bouvet M Chawla SP Singh SR Tsuchiya H & Hoffman RM Oral recombinant methioninase, combined with oral caffeine and injected cisplatinum, overcome cisplatinum-resistance and regresses patient-derived orthotopic xenograft model of osteosarcoma. Anticancer Res. 39(9) 4653 - 4657 2019. DOI: 10.21873/anticanres.13646
33 Sugisawa N Higuchi T Han Q Hozumi C Yamamoto J Tashiro Y Nishino H Kawaguchi K Bouvet M Murata T Unno M & Hoffman RM Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Cancer Chemother Pharmacol. 88(1) 61 - 67 2021. DOI: 10.1007/s00280-021-04261-x
34 Kawaguchi K Miyake K Han Q Li S Tan Y Igarashi K Kiyuna T Miyake M Higuchi T Oshiro H Zhang Z Razmjooei S Wangsiricharoen S Bouvet M Singh SR Unno M & Hoffman RM Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Cancer Lett. 432 251 - 259 2018. DOI: 10.1016/j.canlet.2018.06.016
35 Oshiro H Tome Y Kiyuna T Yoon SN Lwin TM Han Q Tan Y Miyake K Higuchi T Sugisawa N Katsuya Y Park JH Zang Z Razmjooei S Bouvet M Clary B Singh SR Kanaya F Nishida K & Hoffman RM Oral recombinant methioninase overcomes colorectal-cancer liver metastasis resistance to the combination of 5-fluorouracil and oxaliplatinum in a patient-derived orthotopic xenograft mouse model. Anticancer Res. 39(9) 4667 - 4671 2019. DOI: 10.21873/anticanres.13648
36 Strekalova E Malin D Good DM & Cryns VL Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL receptor-2 expression. Clin Cancer Res. 21(12) 2780 - 2791 2015. DOI: 10.1158/1078-0432.CCR-14-2792
37 Higuchi T Kawaguchi K Miyake K Han Q Tan Y Oshiro H Sugisawa N Zhang Z Razmjooei S Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Chawla SP Singh AS Eilber FC Singh SR Tsuchiya H & Hoffman RM Oral recombinant methioninase combined with caffeine and doxorubicin induced regression of a doxorubicin-resistant synovial sarcoma in a PDOX mouse model. Anticancer Res. 38(10) 5639 - 5644 2018. DOI: 10.21873/anticanres.12899
38 Kim MJ Han Q Bouvet M Hoffman RM & Park JH Recombinant oral methioninase (o-rMETase) combined with oxaliplatinum plus 5-fluorouracil improves survival of mice with massive colon-cancer peritoneal carcinomatosis. Anticancer Res. 43(1) 19 - 24 2023. DOI: 10.21873/anticanres.16129
39 Choobin BB Kubota Y Han Q Ardjmand D Morinaga S Mizuta K Bouvet M Tsunoda T & Hoffman RM Recombinant methioninase lowers the effective dose of regorafenib against colon-cancer cells: a strategy for widespread clinical use of a toxic drug. Cancer Diagn Progn. 3(6) 655 - 659 2023. DOI: 10.21873/cdp.10268
40 Morinaga S Han Q Kubota Y Mizuta K Kang BM Sato M Bouvet M Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Higuchi T Tsuchiya H & Hoffman RM Extensive synergy between recombinant methioninase and eribulin against fibrosarcoma cells but not normal fibroblasts. Anticancer Res. 44(3) 921 - 928 2024. DOI: 10.21873/anticanres.16886
41 Sato M Han Q Kubota Y Baranov A Ardjmand D Mizuta K Morinaga S Kang BM Kobayashi N Bouvet M Ichikawa Y Nakajima A & Hoffman RM Recombinant methioninase decreased the effective dose of irinotecan by 15-fold against colon cancer cells: a strategy for effective low-toxicity treatment of colon cancer. Anticancer Res. 44(1) 31 - 35 2024. DOI: 10.21873/anticanres.16785
42 Kubota Y Aoki Y Masaki N Obara K Hamada K Han Q Bouvet M Tsunoda T & Hoffman RM Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease. Biochem Biophys Res Commun. 695 149418 2024. DOI: 10.1016/j.bbrc.2023.149418
43 Morinaga S Han Q Kubota Y Mizuta K Kang BM Sato M Bouvet M Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Higuchi T Tsuchiya H Demura S & Hoffman RM DNA-binding agent trabectedin combined with recombinant methioninase is synergistic to decrease fibrosarcoma cell viability and induce nuclear fragmentation but not synergistic on normal fibroblasts. Anticancer Res. 44(6) 2359 - 2367 2024. DOI: 10.21873/anticanres.17043
44 Morinaga S Han Q Mizuta K Kang BM Sato M Bouvet M Yamamoto N Hayashi K Kimura H Miwa S Igarashi K Higuchi T Tsuchiya H Demura S & Hoffman RM Recombinant methioninase is selectively synergistic with doxorubicin against wild-type fibrosarcoma cells compared to normal cells and overcomes highly-doxorubicin-resistant fibrosarcoma. Anticancer Res. 44(8) 3261 - 3268 2024. DOI: 10.21873/anticanres.17144
45 Kubota Y Han Q Aoki Y Masaki N Obara K Hamada K Hozumi C Wong ACW Bouvet M Tsunoda T & Hoffman RM Synergy of combining methionine restriction and chemotherapy: the disruptive next generation of cancer treatment. Cancer Diagn Progn. 3(3) 272 - 281 2023. DOI: 10.21873/cdp.10212
46 Sato M Han Q Mizuta K Mori R Kang BM Morinaga S Kobayashi N Ichikawa Y Nakajima A & Hoffman RM Extensive shrinkage and long-term stable disease in a teenage female patient with high-grade glioma treated with temozolomide and radiation in combination with oral recombinant methioninase and a low-methionine diet. In Vivo. 38(3) 1459 - 1464 2024. DOI: 10.21873/invivo.13591
47 Hoffman RM & Erbe RW High in vivo rates of methionine biosynthesis in transformed human and malignant rat cells auxotrophic for methionine. Proc Natl Acad Sci USA. 73(5) 1523 - 1527 1976. DOI: 10.1073/pnas.73.5.1523
48 Kaiser P Methionine dependence of cancer. Biomolecules. 10(4) 568 2020. DOI: 10.3390/biom10040568
49 Hoffman RM & Jacobsen SJ Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci USA. 77(12) 7306 - 7310 1980. DOI: 10.1073/pnas.77.12.7306
50 Yano S Li S Han Q Tan Y Bouvet M Fujiwara T & Hoffman RM Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity. Oncotarget. 5(18) 8729 - 8736 2014. DOI: 10.18632/oncotarget.2369
51 Wang Z Yip LY Lee JHJ Wu Z Chew HY Chong PKW Teo CC Ang HY Peh KLE Yuan J Ma S Choo LSK Basri N Jiang X Yu Q Hillmer AM Lim WT Lim TKH Takano A Tan EH Tan DSW Ho YS Lim B & Tam WL Methionine is a metabolic dependency of tumor-initiating cells. Nat Med. 25(5) 825 - 837 2019. DOI: 10.1038/s41591-019-0423-5
52 Bin P Wang C Zhang H Yan Y & Ren W Targeting methionine metabolism in cancer: opportunities and challenges. Trends Pharmacol Sci. 45(5) 395 - 405 2024. DOI: 10.1016/j.tips.2024.03.002
53 Coalson DW Mecham JO Stern PH & Hoffman RM Reduced availability of endogenously synthesized methionine for S-adenosylmethionine formation in methionine-dependent cancer cells. Proc Natl Acad Sci USA. 79(14) 4248 - 4251 1982. DOI: 10.1073/pnas.79.14.4248
54 Stern PH Mecham JO Wallace CD & Hoffman RM Reduced free-methionine in methionine-dependent SV40-transformed human fibroblasts synthesizing apparently normal amounts of methionine. J Cell Physiol. 117(1) 9 - 14 1983. DOI: 10.1002/jcp.1041170103
55 Stern PH & Hoffman RM Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro. 20(8) 663 - 670 1984. DOI: 10.1007/BF02619617
56 Aoki Y Han Q Tome Y Yamamoto J Kubota Y Masaki N Obara K Hamada K Wang JD Inubushi S Bouvet M Clarke SG Nishida K & Hoffman RM Reversion of methionine addiction of osteosarcoma cells to methionine independence results in loss of malignancy, modulation of the epithelial-mesenchymal phenotype and alteration of histone-H3 lysine-methylation. Front Oncol. 12 1009548 2022. DOI: 10.3389/fonc.2022.1009548
57 Yamamoto J Inubushi S Han Q Tashiro Y Sugisawa N Hamada K Aoki Y Miyake K Matsuyama R Bouvet M Clarke SG Endo I & Hoffman RM Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. iScience. 25(4) 104162 2022. DOI: 10.1016/j.isci.2022.104162
58 Yamamoto J Aoki Y Inubushi S Han Q Hamada K Tashiro Y Miyake K Matsuyama R Bouvet M Clarke SG Endo I & Hoffman RM Extent and instability of trimethylation of histone H3 lysine increases with degree of malignancy and methionine addiction. Cancer Genomics Proteomics. 19(1) 12 - 18 2022. DOI: 10.21873/cgp.20299
59 Hoffman RM Jacobsen SJ & Erbe RW Reversion to methionine independence in simian virus 40-transformed human and malignant rat fibroblasts is associated with altered ploidy and altered properties of transformation. Proc Natl Acad Sci. 76(3) 1313 - 1317 1979. DOI: 10.1073/pnas.76.3.1313
60 Hoffman RM Jacobsen SJ & Erbe RW Reversion to methionine independence by malignant rat and SV40-transformed human fibroblasts. Biochem Biophys Res Commun. 82(1) 228 - 234 1978. DOI: 10.1016/0006-291x(78)90600-9
61 Yamamoto J Aoki Y Han Q Sugisawa N Sun YU Hamada K Nishino H Inubushi S Miyake K Matsuyama R Bouvet M Endo I & Hoffman RM Reversion from methionine addiction to methionine independence results in loss of tumorigenic potential of highly-malignant lung-cancer cells. Anticancer Res. 41(2) 641 - 643 2021. DOI: 10.21873/anticanres.14815
62 Abo Qoura L Balakin KV Hoffman RM & Pokrovsky VS The potential of methioninase for cancer treatment. Biochim Biophys Acta Rev Cancer. 1879(4) 189122 2024. DOI: 10.1016/j.bbcan.2024.189122
63 Ghergurovich JM Xu X Wang JZ Yang L Ryseck RP Wang L & Rabinowitz JD Methionine synthase supports tumour tetrahydrofolate pools. Nat Metab. 3(11) 1512 - 1520 2021. DOI: 10.1038/s42255-021-00465-w
64 Sullivan MR Darnell AM Reilly MF Kunchok T Joesch-Cohen L Rosenberg D Ali A Rees MG Roth JA Lewis CA & Vander Heiden MG Methionine synthase is essential for cancer cell proliferation in physiological folate environments. Nat Metab. 3(11) 1500 - 1511 2021. DOI: 10.1038/s42255-021-00486-5
65 Stern PH Wallace CD & Hoffman RM Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol. 119(1) 29 - 34 1984. DOI: 10.1002/jcp.1041190106
66 Mecham JO Rowitch D Wallace C Stern PH & Hoffman RM The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun. 117(2) 429 - 434 1983. DOI: 10.1016/0006-291x(83)91218-4
67 Tan Y Xu M & Hoffman RM Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells In Vitro. Anticancer Res. 30(4) 1041 - 1046 2010.
68 Yamamoto J Han Q Inubushi S Sugisawa N Hamada K Nishino H Miyake K Kumamoto T Matsuyama R Bouvet M Endo I & Hoffman RM Histone methylation status of H3K4me3 and H3K9me3 under methionine restriction is unstable in methionine-addicted cancer cells, but stable in normal cells. Biochem Biophys Res Commun. 533(4) 1034 - 1038 2020. DOI: 10.1016/j.bbrc.2020.09.108